再谈聚乙二醇干扰素α在慢性乙型肝炎个体化治疗中的应用

万谟彬

doi:10.3969/j.issn.1001-5256.2018.05.004

再谈聚乙二醇干扰素α在慢性乙型肝炎个体化治疗中的应用

DOI: 10.3969/j.issn.1001-5256.2018.05.004

万谟彬

上海长海医院感染科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2266
- HTML全文浏览量: 49
- PDF下载量: 405
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-01
- 出版日期: 2018-05-20

Individualized treatment with pegylated interferon-α for chronic hepatitis B

Wan MoBin

Department of Infectious Diseases, Changhai Hospital of Shanghai

摘要

摘要: 抗病毒治疗是慢性乙型肝炎的根本治疗方法,其中聚乙二醇干扰素（PEG-IFN）α是一线治疗药物之一。目前,PEGIFNα个体化治疗方面已经达成多项共识,在临床实践中发挥了重要作用。随着其临床应用不断深入,逐步涌现出了新的临床需求。结合文献以及个人临床实践经验,阐述了PEG-IFNα对慢性乙型肝炎个体化治疗的一些新认识。
- 肝炎,乙型,慢性 /
- 干扰素α /
- 治疗
Abstract: Antiviral therapy is the basic treatment of chronic hepatitis B, and pegylated interferon-α is one of the first-line treatment drugs. At present, several consensuses have been reached on individualized treatment with pegylated interferon-α, which is playing an important role in clinical practice. New clinical demands appear along with the clinical application of pegylated interferon-α. With reference to relevant literature and personal clinical experience, this article elaborates on some knowledge of individualized treatment with pegylated interferon-α for chronic hepatitis B.
- hepatitis B, chronic /
- interferon-alpha /
- therapy

HTML全文

参考文献(11)

[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[2] European Association for the Study of the Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol, 2017, 67 (2) :370-398.

[3]TERRAULT NA, LOK AS, Mc MAHON BJ, et al.Update on prevention, diagnosis, and treatment and of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J].Hepatology, 2018.[Epub ahead of print]

[4]Expert Discussion Group of Interferon in the Treatment of Chronic Hepatitis B.Expert advice on interferon in the treatment of chronic hepatitis B[J].Chin J Infect Dis, 2007, 25 (10) :577-583. (in Chinese) 干扰素治疗慢性乙型肝炎专家讨论组.干扰素治疗慢性乙型肝炎专家建议[J].中华传染病杂志, 2007, 25 (10) :577-583.

[5] WAN MB, WENG XH.Expert advice on interferon in the treatment of chronic hepatitis B (updated in 2010) [J].Chin J Infect Dis, 2010, 28 (4) :193-200. (in Chinese) 万谟彬, 翁心华.干扰素治疗慢性乙型肝炎专家建议 (2010年更新) [J].中华传染病杂志, 2010, 28 (4) :193-200.

[6] WAN MB, WENG XH.Some supplement to the expert advice of interferon in the treatment of chronic hepatitis B[J].Chin J Infect Dis, 2012, 30 (12) :705-710. (in Chinese) 万谟彬, 翁心华.干扰素治疗慢性乙型肝炎专家建议的若干补充[J].中华传染病杂志, 2012, 30 (12) :705-710.

[7]ZHANG WH, ZHANG DZ, DOU XG, et al.Expert consensus on the treatment of chronic hepatitis B by PEG interferon alpha[J].Chin J Hepatol, 2017, 25 (9) :678-686. (in Chinese) 张文宏, 张大志, 窦晓光, 等.聚乙二醇干扰素α治疗慢性乙型肝炎专家共识[J].中华肝脏病杂志, 2017, 25 (9) :678-686.

[8]NING Q, HAN M, SUN Y, et al.Switching from entecavir to Peg IFN alfa-2a in patients with HBe Ag-positive chronic hepatitis B:a randomised open-label trial (OOST trial) [J].J Hepatol, 2014, 61 (4) :777-784.

[9] CAO Z, LIU Y, MA L, et al.A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J].Hepatolog, 2017, 66 (4) :1058-1066.

[10]SUN J, MA H, XIE Q, et al.Response-guided paginterferon therapy in patients with HBe Ag-positive chronic hepatitis B:a randomized controlled study[J].J Hepatol, 2016, 65 (4) :674-682.

[11]HU P, DOU XG, XIE Q, et al.High HBs Ag loss rate in HBe Ag loss CHB patients SWITCH from NUC to Peg-IFN alfa-2a (NEW SWITCH study) [J].Hepatol Int, 2017, 11 (Suppl 1) :s1091-s1093.

施引文献

资源附件(0)

访问统计